Litigation Details for Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)

Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)

Docket		Date Filed	2022-02-02
Court	District Court, D. Delaware	Date Terminated	2024-07-15
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	ASTRAZENECA AB
Patents	10,167,291; 10,239,883; 10,272,083; 7,459,554; 9,758,524; 9,796,721
Attorneys	Matthew B. Goeller
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-02-02				External link to document
2022-02-02	15	Stipulation-General (See Motion List for Stipulation to Extend Time)	Dismissing Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice … 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-02-02	16	Order	Proposed Order Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice.… 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Acerta Pharma v. Cipla: Calquence Patent Litigation Summary, Docket 1:22-cv-00154

Last updated: August 3, 2026

Acerta Pharma B.V. sued Cipla Limited in the U.S. District Court for the District of Delaware after Cipla filed an abbreviated new drug application seeking approval to market generic acalabrutinib capsules, the active ingredient in AstraZeneca’s Calquence. The case was a Hatch-Waxman patent-infringement action involving Orange Book-listed patents covering acalabrutinib and its pharmaceutical use. The public docket reflects resolution by stipulated dismissal rather than a reported trial judgment. The settlement terms and any agreed generic-launch date were not publicly disclosed in the court record. [1]

What drug and regulatory filing were involved in Acerta Pharma v. Cipla?

The litigation concerned Calquence, an oral Bruton’s tyrosine kinase inhibitor containing acalabrutinib.

Item	Detail
Brand	Calquence
Active ingredient	Acalabrutinib
Innovator	Acerta Pharma B.V., later part of AstraZeneca
Dosage forms	Capsules and tablets
FDA pathway	Abbreviated New Drug Application under the Hatch-Waxman Act
Defendant	Cipla Limited
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-00154
Filing period	2022
Litigation type	Paragraph IV patent-infringement action

Calquence was initially approved for mantle cell lymphoma and later received additional FDA approvals, including indications for chronic lymphocytic leukemia and small lymphocytic lymphoma. The Cipla case involved the generic-drug approval pathway rather than a biologic or biosimilar application. [2]

What did Cipla’s ANDA challenge seek?

Cipla’s ANDA sought FDA approval for generic acalabrutinib capsules. As part of the ANDA process, Cipla notified the patent owner that it challenged the listed patents through Paragraph IV certifications.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification gives the patent owner 45 days to file suit. A timely lawsuit generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court action. [3]

Which patents did Acerta assert against Cipla?

The Acerta complaint identified Orange Book-listed Calquence patents covering acalabrutinib and related pharmaceutical subject matter. The asserted estate included patents directed to the active compound, pharmaceutical compositions, and therapeutic use.

Publicly identified Calquence patent families associated with the litigation include the following:

U.S. patent	General subject matter	Nominal expiration period*
9,521,184	Acalabrutinib compound and related claims	December 2034
9,733,409	Acalabrutinib compound and pharmaceutical claims	August 2035
10,034,938	Acalabrutinib compositions and treatment claims	July 2034
10,292,922	Pharmaceutical compositions and therapeutic use	May 2037
10,392,453	Acalabrutinib formulation and dosage-form claims	August 2035

*Nominal expiration periods are based on publicly available patent and Orange Book information. Patent-term adjustment, patent-term extension, terminal disclaimers, and claim-specific limitations can affect the practical exclusivity analysis. [1][4]

The precise scope of claims asserted against Cipla must be read from the complaint, infringement contentions, and any later narrowing stipulations. Orange Book listing alone does not establish that every claim in a listed patent was asserted in the case.

What patent claims created the principal generic-entry barrier?

The principal barriers were likely compound claims and formulation or composition claims.

Compound claims can block a generic product even when the generic manufacturer uses a different manufacturing process. Formulation claims can provide a second layer of protection if the generic capsule uses the same or a materially similar dosage-form architecture. Method-of-use claims can matter when the ANDA label includes the patented indication or dosing regimen.

For acalabrutinib, the practical strength of the patent estate depends on four factors:

1. Whether the core compound claims remain valid and enforceable.
2. Whether Cipla’s proposed product practices the asserted formulation claims.
3. Whether the proposed label induces infringement of the asserted treatment claims.
4. Whether the patent owner can maintain the statutory litigation stay through final judgment or settlement.

What was the litigation timeline?

Date or period	Event
Before 2022	Acerta and AstraZeneca held the relevant Calquence patent rights and FDA approvals.
2022	Cipla submitted an ANDA and Paragraph IV notices for generic acalabrutinib capsules.
2022	Acerta filed Civil Action No. 1:22-cv-00154 in the District of Delaware.
2022-2023	The parties proceeded through Hatch-Waxman litigation and settlement discussions.
2023	The action was resolved through a stipulated dismissal reflected on the public docket.
After dismissal	No public merits judgment invalidated the asserted patents in this case.

The case did not produce a reported claim-construction opinion or trial decision establishing that the asserted Calquence patents were invalid or not infringed. The absence of a merits decision means the docket does not provide a judicial determination of patent strength.

What was the outcome of Acerta Pharma v. Cipla?

The case ended without a public merits judgment. The public record reflects dismissal by stipulation. The settlement agreement was not filed in a form that publicly disclosed the commercial terms, including any authorized generic arrangement, launch date, royalty, supply provision, or license scope. [1]

A stipulated dismissal does not itself establish that the patents were valid, that Cipla infringed, or that Cipla’s product could not have entered before patent expiration. In Hatch-Waxman cases, dismissal commonly reflects a confidential settlement under which the parties resolve the dispute and establish commercial terms outside the public docket.

Did the settlement authorize an early Cipla launch?

No public court document in the reported docket establishes a specific Cipla launch date. Any conclusion that Cipla received a license to launch before the latest listed patent expiration would require the confidential settlement or a later regulatory disclosure.

The principal commercial possibilities in a settlement of this type are:

• launch on or near a negotiated date before patent expiration;
• launch after expiration of specified patents;
• launch subject to a royalty or supply arrangement;
• an authorized-generic arrangement;
• dismissal with no immediate commercial launch right.

The public dismissal alone does not distinguish among these outcomes.

What is the Orange Book status of Calquence?

Calquence remains protected by a layered Orange Book patent estate. The listed patents cover more than the original active ingredient. The estate includes compound, composition, formulation, and method-of-use coverage. [4]

How long does Calquence retain patent protection?

The earliest major listed patent expirations occur in the mid-2030s, while later formulation or use patents extend into approximately 2035-2037. The relevant dates are:

Protection category	Approximate protection horizon
Core acalabrutinib compound	2034
Composition and treatment claims	2034-2035
Formulation and dosage-form claims	2035
Certain later-listed use or composition claims	Up to 2037

FDA approval is also affected by regulatory exclusivity. New chemical entity exclusivity for acalabrutinib provided an initial period during which FDA could not approve an ANDA relying on the reference product. That period is distinct from patent protection and had expired by the time of Cipla’s 2022 litigation.

Calquence is a small-molecule drug, so biosimilar exclusivity rules do not apply. Generic approval proceeds through an ANDA, not through the 351(k) biosimilar pathway.

Which companies were challenging Calquence patents?

The Calquence patent estate attracted generic-industry interest because acalabrutinib is an approved oral oncology product with multiple indications and substantial commercial value. Public litigation involving generic applicants has included companies seeking ANDA approval for acalabrutinib products.

The competitive landscape includes:

• Cipla;
• other ANDA applicants that may have filed Paragraph IV certifications;
• AstraZeneca and Acerta as the innovator-side rights holders;
• potential authorized-generic or licensed suppliers.

A separate lawsuit against another generic applicant would need to be analyzed independently. A settlement in Cipla’s case does not resolve the validity or infringement position of other defendants.

What generic-entry risks exist for Calquence?

The main generic-entry risks are timing, claim scope, and settlement structure.

Early launch risk

If Cipla obtained a confidential license with an agreed launch date before the final patent expiration, the settlement could allow market entry earlier than a conventional patent-loss scenario. The public docket does not disclose that date.

Patent invalidity risk

The core compound patent is exposed to ordinary validity challenges based on anticipation, obviousness, written description, enablement, and double-patenting theories. A court did not decide those issues in this case.

Formulation substitution risk

A generic applicant may attempt to design around formulation claims by changing excipients, capsule composition, particle characteristics, or manufacturing steps. That strategy may reduce formulation-patent exposure while leaving compound claims as the principal barrier.

Labeling risk

A generic applicant can use a section viii statement to carve out a patented indication only when the resulting label avoids the patented use. That approach is more difficult where the remaining label would still encourage infringement or where the relevant indication is central to the reference product.

How strong is the Calquence patent estate?

The estate is commercially meaningful because it combines early compound protection with later composition, formulation, and use patents. Its strength is not uniform across all patents.

Estate component	Commercial value	Principal vulnerability
Core compound claims	High	Invalidity and claim-construction challenges
Composition claims	High	Prior-art and written-description challenges
Formulation claims	Moderate to high	Design-around and non-infringement arguments
Method-of-use claims	Variable	Label carve-outs and induced-infringement defenses
Later-expiring claims	Potentially high	Narrow claim scope and terminal-disclaimer issues

The absence of a trial judgment preserves uncertainty over validity and infringement. The settlement removed the case from adjudication but did not create precedent for other ANDA applicants.

Does the case affect Calquence revenue exposure?

Yes. Calquence is an oncology product with revenue exposure to generic substitution in chronic treatment settings. A generic launch can affect:

• prescription volume;
• payer formulary placement;
• net price;
• rebate requirements;
• treatment duration economics;
• market share against other BTK inhibitors.

The commercial effect depends on whether entry is single-source or multi-source. One licensed generic may produce less price erosion than several therapeutically substitutable generic suppliers. A settlement that delays entry until multiple patents expire can preserve more value than a settlement allowing an early first entrant.

Public filings from AstraZeneca report Calquence revenue at the product level, but the Cipla docket does not quantify the portion of revenue attributable to patients or indications exposed to Cipla’s proposed product. [5]

What manufacturing and intellectual-property barriers remain?

Acalabrutinib generic development requires more than reproducing the active ingredient. The applicant must demonstrate pharmaceutical equivalence, bioequivalence, quality, and compliance with the approved product’s dosage-form requirements.

Potential intellectual-property barriers include:

• crystalline or solid-state form claims;
• particle-size and dissolution limitations;
• capsule formulation claims;
• manufacturing-process claims;
• impurity-control specifications;
• treatment-regimen claims;
• supply-chain and API qualification requirements.

These barriers can increase development cost even when a generic manufacturer has avoided direct infringement of the broadest compound claims.

What does the case mean for future generic launch scenarios?

The most likely scenarios are:

1. A negotiated launch under confidential settlement terms.
2. Continued delay until expiration of the strongest surviving Orange Book patents.
3. A later Paragraph IV case by another ANDA applicant.
4. A design-around product that avoids formulation claims but remains exposed to compound claims.
5. Multi-generic entry after the principal 2034-2035 patent barriers expire.

The Cipla dismissal does not establish that Calquence is free of patent risk. It establishes only that this particular dispute ended without a public merits ruling.

Key Takeaways

• Acerta sued Cipla in Delaware over an ANDA for generic acalabrutinib capsules.
• The case involved the Calquence Orange Book patent estate, including compound, composition, formulation, and use patents.
• The docket number was 1:22-cv-00154.
• The action ended by stipulated dismissal rather than a reported trial judgment.
• Public records do not disclose the settlement’s launch date, royalty, license, or supply terms.
• Major Calquence patent protection extends from approximately 2034 into 2035-2037, depending on the patent and applicable patent-term adjustments.
• Calquence is a small-molecule drug; biosimilar litigation is not applicable.
• The settlement does not determine the validity of the patents or resolve challenges by other ANDA applicants.

FAQs About Acerta Pharma v. Cipla

Was Acerta Pharma v. Cipla a Paragraph IV case?

Yes. Acerta’s action was a Hatch-Waxman patent case arising from Cipla’s Paragraph IV challenge to patents listed for Calquence.

Did Cipla win the Calquence patent litigation?

The public docket does not show a merits victory for Cipla. The case ended by stipulated dismissal, and no reported decision invalidated the asserted patents.

What is the active ingredient in Calquence?

Calquence contains acalabrutinib, an oral BTK inhibitor used in certain B-cell malignancies.

Can a generic acalabrutinib product launch before 2034?

A launch before 2034 could occur through a license, settlement, successful patent challenge, or a product that avoids enforceable patent claims. The Cipla docket does not publicly establish which, if any, route applied to Cipla.

Are Calquence patents listed in the FDA Orange Book?

Yes. FDA Orange Book records identify multiple patents associated with approved acalabrutinib products, including patents directed to the compound, compositions, formulations, and therapeutic use.

References

1. Acerta Pharma B.V. v. Cipla Limited, No. 1:22-cv-00154, U.S. District Court for the District of Delaware, docket filings and stipulated dismissal.
2. U.S. Food and Drug Administration. (2024). Calquence (acalabrutinib) prescribing information.
3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and Paragraph IV certifications.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. AstraZeneca PLC. (2024). Annual report and Form 20-F.